You have 9 free searches left this month | to do more
Showing 1 - 25 of
2,194 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
Recruiting
  • Immunotherapy
  • +3 more
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
2021-07-11
Jul 11, 2021
T
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Recruiting
  • MSI-H Advanced Colorectal Cancer
  • Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
2021-09-03
Sep 3, 2021
P
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Recruiting
  • Colorectal Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital and Institute
2021-07-31
Jul 31, 2021
S
An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors
Not yet recruiting
  • To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer
  • No interventions
  • Beijing, Beijing, China
    Beijing Cancer Hospital
2020-11-26
Nov 26, 2020
G
Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer
Recruiting
  • Colorectal Cancer
  • Carpi, Modena, Italy
    Ospedale Ramazzini
2020-10-27
Oct 27, 2020
S
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Recruiting
  • DMMR Colorectal Cancer
  • +2 more
  • PD-1 Antibody
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
2021-09-22
Sep 22, 2021
S
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022
T
Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
Not yet recruiting
  • Colorectal Neoplasm
  • Combination of Fruquintinib and Camrelizumab
  • Nanjing, Jiangsu, China
    the First Affiliated Hospital of Nanjing Medical University
2021-04-27
Apr 27, 2021
B
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Recruiting
  • MSI-H/dMMR Solid Tumors
  • Tislelizumab (BGB-A317)
  • Beijing, Beijing, China
    Beijing Cancer Hospital
2022-03-24
Mar 24, 2022
D
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Recruiting
  • Metastatic Endometrial Cancer
  • Chicago, Illinois
  • +3 more
2021-06-01
Jun 1, 2021
U
Anti-PD-1 +/- RT for MSI-H Solid Tumors - 2021
Withdrawn
  • Microsatellite Instability High
  • +2 more
  • Denver, Colorado
    University of Colorado Hospital
2021-11-17
Nov 17, 2021
A
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Active, not recruiting
  • Metastatic Colorectal Cancer
  • Seoul, Korea, Republic of
    Asan Medical Center
2020-08-27
Aug 27, 2020
W
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Recruiting
  • Anti-PD-1 Antibody
  • +4 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
2020-12-02
Dec 2, 2020
F
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
Not yet recruiting
  • Locally Advanced Rectal Cancer
  • PD-1 antibody
  • +3 more
  • Shanghai, Shanghai, China
    Zhen Zhang
2020-06-01
Jun 1, 2020
T
Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer
Unknown status
  • Locally Advanced Colon Cancer
  • Xiamen, Fujian, China
    Yefeng
2020-05-11
May 11, 2020
O
Combination Immunotherapy in Rare Cancers Under InvesTigation
Recruiting
  • Advanced Biliary Tract Cancer
  • +3 more
  • Albury, New South Wales, Australia
  • +8 more
2022-03-31
Mar 31, 2022
M
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Recruiting
  • Solid Tumors
  • Identified by NGS, PCR or IHC
  • Basking Ridge, New Jersey
  • +6 more
2022-03-01
Mar 1, 2022
A
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Unknown status
  • Metastatic Colorectal Cancer
  • Seoul, Songpa, Korea, Republic of
    Asan Medical Center
2020-04-01
Apr 1, 2020
R
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer
Recruiting
  • Gastric Cancer Stage III
  • Shanghai, China
    Ethics Committee of Renji Hospital, School of Medicine, Shanghai
2020-04-16
Apr 16, 2020
S
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Recruiting
  • Colorectal Cancer Stage II
  • +3 more
  • Guangzhou, Guangdong, China
    Medical Oncology,Sun Yat-sen University Cancer Center
2020-03-11
Mar 11, 2020
E
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
Recruiting
  • Advanced Microsatellite Stable Colorectal Carcinoma
  • +5 more
  • Atlanta, Georgia
  • +2 more
2021-10-29
Oct 29, 2021
Q
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
Not yet recruiting
  • Advanced Malignant Tumor
  • Shanghai, Shanghai, China
  • +1 more
2020-03-26
Mar 26, 2020
C
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
Not yet recruiting
  • MSI-H or dMMR Advanced Solid Tumors
  • Beijing, Beijing, China
  • +8 more
2020-02-28
Feb 28, 2020
X
A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer
Unknown status
  • Colorectal Cancer
  • Shanghai, Shanghai, China
    Zhongshan Hospital
2019-10-05
Oct 5, 2019
C
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Recruiting
  • Non-small Cell Lung Cancer
  • +13 more
  • Atlanta, Georgia
  • +4 more
2022-03-01
Mar 1, 2022